Search Results
Your search for all items matches 504 pages
Showing 501 - 504Breakthrough Therapy Designation for Lambrolizumab for the Treatment of Advanced Melanoma
Merck has announced that the U.S. Food and Drug Administration has designated lambrolizumab (MK-3475) as a Breakthrough Therapy for the treatment of patients with advanced melanoma. Lambrolizumab is Merck’s investigational antibody therapy targeting the programmed death receptor (PD-1) that...
New Imaging Agent Enables Better Cancer Detection, More Accurate Staging
Researchers at the University of California, San Diego School of Medicine have shown that a new imaging dye, designed and developed at UC San Diego Moores Cancer Center, is an effective agent in detecting and mapping cancers that have reached the lymph nodes. The radioactive dye technetium Tc-99m...
Amgen Announces Results of Phase III Talimogene Laherparepvec Trial in Late-stage Melanoma
Amgen has announced results from a phase III trial evaluating the efficacy and safety of talimogene laherparepvec for the treatment of unresected stage IIIB, IIIC, or IV melanoma compared to treatment with subcutaneous granulocyte-macrophage colony-stimulating factor (GM-CSF). Talimogene...
New Website Raises Awareness of Uveal Melanoma and the Importance of Prognostic Testing
Launch of a website created to educate newly diagnosed patients, their families, and health-care providers about uveal melanoma, was announced recently by Castle Biosciences, Inc, a developer of prognostic tests for rare cancers. The website, MyUvealMelanoma.com, addresses the treatment of uveal...
